English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 49378/84106 (59%)
造访人次 : 7368149      在线人数 : 76
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻

    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/93104

    题名: Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
    作者: Huang, Chih-Chia;Wei, I-Hua;Huang, Chieh-Liang;Chen, Kuang-Ti;Tsai, Mang-Hung;Tsai, Priscilla;Tun, Rene;Huang, Kuo-Hao;Chang, Yue-Cune;Lane, Hsien-Yuan;Tsai, Guochuan Emil
    贡献者: 淡江大學數學學系
    关键词: Anxiety;elevated plus maze;forced swimming test;glutamate;N-methyl-D-aspartate;sarcosine
    日期: 2013-11
    上传时间: 2013-11-21 13:57:08 (UTC+8)
    出版者: Philadelphia: Elsevier Inc.
    摘要: Background
    Antidepressants, aiming at monoaminergic neurotransmission, exhibit delayed onset of action, limited efficacy, and poor compliance. Glutamatergic neurotransmission is involved in depression. However, it is unclear whether enhancement of the N-methyl-D-aspartate (NMDA) subtype glutamate receptor can be a treatment for depression.

    We studied sarcosine, a glycine transporter-I inhibitor that potentiates NMDA function, in animal models and in depressed patients. We investigated its effects in forced swim test, tail suspension test, elevated plus maze test, novelty-suppressed feeding test, and chronic unpredictable stress test in rats and conducted a 6-week randomized, double-blinded, citalopram-controlled trial in 40 patients with major depressive disorder. Clinical efficacy and side effects were assessed biweekly, with the main outcomes of Hamilton Depression Rating Scale, Global Assessment of Function, and remission rate. The time course of response and dropout rates was also compared.

    Sarcosine decreased immobility in the forced swim test and tail suspension test, reduced the latency to feed in the novelty-suppressed feeding test, and reversed behavioral deficits caused by chronic unpredictable stress test, which are characteristics for an antidepressant. In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment. Sarcosine-treated patients were much more likely and quicker to remit and less likely to drop out. Sarcosine was well tolerated without significant side effects.

    Our preliminary findings suggest that enhancing NMDA function can improve depression-like behaviors in rodent models and in human depression. Establishment of glycine transporter-I inhibition as a novel treatment for depression waits for confirmation by further proof-of-principle studies.
    關聯: Biological Psychiatry 74(10), pp.734-741
    DOI: 10.1016/j.biopsych.2013.02.020
    显示于类别:[數學學系暨研究所] 期刊論文


    档案 描述 大小格式浏览次数



    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回馈